HC Wainwright reiterated their buy rating on shares of Arcadia Biosciences (NASDAQ:RKDA – Free Report) in a report issued on Wednesday morning, Benzinga reports. HC Wainwright currently has a $6.00 target price on the basic materials company’s stock. HC Wainwright also issued estimates for Arcadia Biosciences’ Q3 2024 earnings at ($0.77) EPS, Q4 2024 earnings at ($0.50) EPS, FY2024 earnings at ($1.70) EPS, Q1 2025 earnings at ($0.37) EPS, Q2 2025 earnings at $0.66 EPS, Q3 2025 earnings at ($0.12) EPS, Q4 2025 earnings at ($0.09) EPS and FY2025 earnings at $0.12 EPS.
Several other research firms also recently weighed in on RKDA. StockNews.com started coverage on shares of Arcadia Biosciences in a research report on Monday, August 19th. They issued a sell rating on the stock. Lake Street Capital upgraded Arcadia Biosciences to a strong-buy rating in a research report on Tuesday, May 14th.
Check Out Our Latest Analysis on Arcadia Biosciences
Arcadia Biosciences Trading Up 0.7 %
Arcadia Biosciences (NASDAQ:RKDA – Get Free Report) last posted its earnings results on Tuesday, August 13th. The basic materials company reported $0.78 earnings per share for the quarter, missing analysts’ consensus estimates of $1.27 by ($0.49). The firm had revenue of $1.31 million during the quarter, compared to the consensus estimate of $0.95 million. Arcadia Biosciences had a negative net margin of 127.29% and a negative return on equity of 57.51%. During the same period in the prior year, the company posted ($2.64) EPS. Research analysts forecast that Arcadia Biosciences will post -2.29 earnings per share for the current year.
About Arcadia Biosciences
Arcadia Biosciences, Inc produces and markets plant-based food and beverage products in the United States. The company develops crop improvements primarily in wheat to enhance farm economics by improving the performance of crops in the field, as well as their value as food ingredients. Its food, beverage, and body case products include GoodWheat, Zola coconut water, ProVault topical pain relief, and SoulSpring.
Further Reading
- Five stocks we like better than Arcadia Biosciences
- Trading Stocks: RSI and Why it’s Useful
- CAVA Stock Rallies as Earnings Confirm It’s a Top Growth Play
- What is the Dogs of the Dow Strategy? Overview and Examples
- MarketBeat Week in Review – 8/19 – 8/23
- TSX Venture Exchange (Formerly Canadian Venture Exchange)
- 3 High Short-Interest Stocks Poised for a Rate Cut Squeeze
Receive News & Ratings for Arcadia Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcadia Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.